Table 3 Change in CTCs over time.

From: Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid

 

Number

Median (range) CTC/mL

Recurrence Rate [n (%)]

Baseline

45

0.2 (0– 8.6)

 

6 months

30

0.25 (0–1.2)

1 (11.1%)

12 months

22

0.0 (0.0–1.5)

3 (33.3%)

18 months

17

0.1 (0.0–5.6)

4 (44.4%)

24 months

23

0.2 (0–12)

5 (55.6%)

  1. CTC circulating tumor cell.
Back to article page